• Profile
Close

Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression

Lung Cancer Sep 16, 2020

Frank MS, Bodtger U, Høegholm A, et al. - Given that re-biopsy in progressive advanced non-small-cell lung cancer (NSCLC) following first line treatment may unveil information regarding evolving tumor biology during treatment, researchers focused on the feasibility, complication risk, as well as clinical relevance of performing re-biopsy systematically. In this prospective single-center study, they analyzed NSCLC patients with advanced, non-targetable disease taking first line systemic treatment. Re-biopsy was performed in 51 patients with progressive advanced NSCLC. Chemotherapy-treated patients had a significantly higher likelihood of PD-L1 tumor proportion score change vs those treated with immunotherapy. Based on the findings, experts concluded that it is feasible to perform re-biopsy, and re-biopsy was associated with low risk of complications and can have clinical relevance in patients with suspected progression in advanced NSCLC.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay